{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T04:53:26Z","timestamp":1760244806829,"version":"build-2065373602"},"reference-count":31,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2022,12,28]],"date-time":"2022-12-28T00:00:00Z","timestamp":1672185600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JPM"],"abstract":"<jats:p>Hypertriglyceridemia (HTG) remains a risk-enhancing factor of atherosclerotic cardiovascular disease. We aimed to report real-world data on the management of patients with type V hyperlipoproteinemia (HLP5), an uncommon phenotype of dyslipidemia characterized by fasting chylomicronemia and severe HTG. Between July 2018 and May 2021, 90 patients with HTG, including 83 patients with type IV hyperlipoproteinemia (HLP4) and 7 patients with HLP5, were identified by plasma apolipoprotein B (apoB) and lipoprotein electrophoresis. Patients with HLP5 were younger, had higher total cholesterol (TC) (264.9 \u00b1 26.7 mg\/dL vs. 183.9 \u00b1 26.1 mg\/dL; p &lt; 0.01) and higher triglyceride (TG) (1296.7 \u00b1 380.5 mg\/dL vs. 247.6 \u00b1 96.1 mg\/dL; p &lt; 0.01), and had lower high-density lipoprotein cholesterol (HDL-C) (30.6 \u00b1 4.8 mg\/dL vs. 40.5 \u00b1 8.7 mg\/dL; p &lt; 0.01) and lower low-density lipoprotein cholesterol (LDL-C) (62.9 \u00b1 16.4 vs. 103.0 \u00b1 21.1 mg\/dL; p &lt; 0.01) compared with patients with HLP4. Despite an aggressive use of statin and fenofibrate with greater reductions in TG (-65.9 \u00b1 13.7% vs. -27.9 \u00b1 30.5%; p &lt; 0.01) following 6 months of treatment, patients with HLP5 had persistent HTG (440.1 \u00b1 239.0 mg\/dL vs. 173.9 \u00b1 94.8 mg\/dL; p &lt; 0.01) and an increase in LDL-C (28.3 \u00b1 57.2% vs. -19.5 \u00b1 32.0%; p &lt; 0.01) compared with patients with HLP4. Our findings highlight that the lack of novel TG-lowering medications and management guidelines remains an unmet medical need in patients with HLP5. Closely monitoring lipid profiles, full assessment of individual\u2019s risk of cardiovascular disease, and emphasis on medication adherence are of clinical importance.<\/jats:p>","DOI":"10.3390\/jpm13010068","type":"journal-article","created":{"date-parts":[[2022,12,29]],"date-time":"2022-12-29T02:59:01Z","timestamp":1672282741000},"page":"68","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Management of Patients with Type V Hyperlipoproteinemia: An Uncommon Phenotype of Dyslipidemia with Chylomicronemia and Severe Hypertriglyceridemia"],"prefix":"10.3390","volume":"13","author":[{"given":"Ya-Hui","family":"Chang","sequence":"first","affiliation":[{"name":"Department of Medicine, MacKay Medical College, New Taipei City 252005, Taiwan"},{"name":"Department of Pharmacy, MacKay Memorial Hospital, Taipei 104217, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dai-Yi","family":"Lin","sequence":"additional","affiliation":[{"name":"Department of Cardiology, MacKay Memorial Hospital, Taipei 104217, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chia-Ling","family":"Tsai","sequence":"additional","affiliation":[{"name":"Department of Cardiology, MacKay Memorial Hospital, Taipei 104217, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chih-Hung","family":"Liang","sequence":"additional","affiliation":[{"name":"Department of Medical Education, MacKay Memorial Hospital, Taipei 104217, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu-Ting","family":"Yu","sequence":"additional","affiliation":[{"name":"Department of Medical Education, MacKay Memorial Hospital, Taipei 104217, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi-Lin","family":"Hsieh","sequence":"additional","affiliation":[{"name":"Department of Medical Education, MacKay Memorial Hospital, Taipei 104217, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jen-Yu","family":"Chuang","sequence":"additional","affiliation":[{"name":"Department of Medical Education, MacKay Memorial Hospital, Taipei 104217, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi-Han","family":"Chen","sequence":"additional","affiliation":[{"name":"School of Public Health, College of Public Health, Taipei Medical University, Taipei 110301, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3206-0908","authenticated-orcid":false,"given":"Hung-I","family":"Yeh","sequence":"additional","affiliation":[{"name":"Department of Medicine, MacKay Medical College, New Taipei City 252005, Taiwan"},{"name":"Department of Cardiology, MacKay Memorial Hospital, Taipei 104217, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chao-Feng","family":"Lin","sequence":"additional","affiliation":[{"name":"Department of Medicine, MacKay Medical College, New Taipei City 252005, Taiwan"},{"name":"Department of Cardiology, MacKay Memorial Hospital, Taipei 104217, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2022,12,28]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1056\/NEJM196701262760406","article-title":"Fat transport in lipoproteins--an integrated approach to mechanisms and disorders","volume":"276","author":"Fredrickson","year":"1967","journal-title":"N. Engl. J. Med."},{"key":"ref_2","first-page":"891","article-title":"Classification of hyperlipidaemias and hyperlipoproteinaemias","volume":"43","author":"Beaumont","year":"1970","journal-title":"Bull. World Health Organ."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"3168","DOI":"10.1016\/j.jacc.2018.11.002","article-title":"2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA Guideline on the Management of Blood Cholesterol: Executive Summary: A Report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines","volume":"73","author":"Grundy","year":"2019","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","article-title":"2019 ESC\/EAS Guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk","volume":"41","author":"Mach","year":"2020","journal-title":"Eur. Heart J."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1038\/nrendo.2010.50","article-title":"Diagnosis and treatment of apolipoprotein B dyslipoproteinemias","volume":"6","author":"Sniderman","year":"2010","journal-title":"Nat. Rev. Endocrinol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.5114\/aoms.2019.86964","article-title":"Modern prevalence of the Fredrickson-Levy-Lees dyslipidemias: Findings from the Very Large Database of Lipids and National Health and Nutrition Examination Survey","volume":"16","author":"Sathiyakumar","year":"2019","journal-title":"Arch. Med. Sci."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"2762","DOI":"10.1161\/01.CIR.88.6.2762","article-title":"Plasma lipoproteins and progression of coronary artery disease evaluated by angiography and clinical events","volume":"88","author":"Phillips","year":"1993","journal-title":"Circulation"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1007\/BF00145358","article-title":"IDL, VLDL, chylomicrons and atherosclerosis","volume":"8","author":"Nordestgaard","year":"1992","journal-title":"Eur. J. Epidemiol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1016\/j.jacc.2007.10.038","article-title":"Impact of triglyceride levels beyond low-density lipoprotein cholesterol after acute coronary syndrome in the PROVE IT-TIMI 22 trial","volume":"51","author":"Miller","year":"2008","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1161\/CIRCULATIONAHA.106.637793","article-title":"Triglycerides and the risk of coronary heart disease: 10,158 incident cases among 262,525 participants in 29 Western prospective studies","volume":"115","author":"Sarwar","year":"2007","journal-title":"Circulation"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.1093\/eurheartj\/ehs431","article-title":"Genetically elevated non-fasting triglycerides and calculated remnant cholesterol as causal risk factors for myocardial infarction","volume":"34","author":"West","year":"2013","journal-title":"Eur. Heart J."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1373\/clinchem.2013.219881","article-title":"Low nonfasting triglycerides and reduced all-cause mortality: A mendelian randomization study","volume":"60","author":"Thomsen","year":"2014","journal-title":"Clin. Chem."},{"key":"ref_13","first-page":"354","article-title":"Improvement of Goal Attainment of Low-Density Lipoprotein Cholesterol in High-Risk Patients by Individualized Target Value Reminding Approach","volume":"15","author":"Lin","year":"2021","journal-title":"Int. J. Gerontol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/S0167-5273(02)00250-4","article-title":"Low density lipoprotein particles are small in patients with coronary vasospasm","volume":"87","author":"Miwa","year":"2003","journal-title":"Int. J. Cardiol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1016\/j.jacc.2021.06.011","article-title":"2021 ACC Expert Consensus Decision Pathway on the Management of ASCVD Risk Reduction in Patients with Persistent Hypertriglyceridemia: A Report of the American College of Cardiology Solution Set Oversight Committee","volume":"78","author":"Virani","year":"2021","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"981","DOI":"10.3390\/nu5030981","article-title":"Hypertriglyceridemia","volume":"5","author":"Brahm","year":"2013","journal-title":"Nutrients"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"4189","DOI":"10.1093\/hmg\/ddp361","article-title":"A polygenic basis for four classical Fredrickson hyperlipoproteinemia phenotypes that are characterized by hypertriglyceridemia","volume":"18","author":"Hegele","year":"2009","journal-title":"Hum. Mol. Genet."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"2218","DOI":"10.1161\/ATVBAHA.115.305614","article-title":"Kinetic and Related Determinants of Plasma Triglyceride Concentration in Abdominal Obesity: Multicenter Tracer Kinetic Study","volume":"35","author":"Watts","year":"2015","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"4791","DOI":"10.1093\/eurheartj\/ehab551","article-title":"Triglyceride-rich lipoproteins and their remnants: Metabolic insights, role in atherosclerotic cardiovascular disease, and emerging therapeutic strategies-a consensus statement from the European Atherosclerosis Society","volume":"42","author":"Ginsberg","year":"2021","journal-title":"Eur. Heart J."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1194\/jlr.P119000543","article-title":"LDL subclass lipidomics in atherogenic dyslipidemia: Effect of statin therapy on bioactive lipids and dense LDL","volume":"61","author":"Chapman","year":"2020","journal-title":"J. Lipid Res."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/j.ejim.2014.08.008","article-title":"Current knowledge of hypertriglyceridemic pancreatitis","volume":"25","author":"Valdivielso","year":"2014","journal-title":"Eur. J. Intern. Med."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.arcmed.2017.11.017","article-title":"Optimizing Non-Pharmacologic Management of Hypertriglyceridemia","volume":"48","author":"Byrne","year":"2017","journal-title":"Arch. Med. Res."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1016\/S0140-6736(07)60527-3","article-title":"Japan EPA lipid intervention study (JELIS) Investigators. Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): A randomised open-label, blinded endpoint analysis","volume":"369","author":"Yokoyama","year":"2007","journal-title":"Lancet"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1812792","article-title":"REDUCE-IT Investigators. Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia","volume":"380","author":"Bhatt","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"ACCORD Study Group, Ginsberg, H.N., Elam, M.B., Lovato, L.C., Crouse, J.R., Leiter, L.A., Linz, P., Friedewald, W.T., Buse, J.B., and Gerstein, H.C. (2010). Effects of combination lipid therapy in type 2 diabetes mellitus. N. Engl. J. Med., 362, 1563\u20131574.","DOI":"10.1056\/NEJMoa1001282"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1016\/S0140-6736(05)67667-2","article-title":"FIELD study investigators. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): Randomised controlled trial","volume":"366","author":"Keech","year":"2005","journal-title":"Lancet"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/s12944-021-01434-8","article-title":"Pemafibrate decreases triglycerides and small, dense LDL, but increases LDL-C depending on baseline triglycerides and LDL-C in type 2 diabetes patients with hypertriglyceridemia: An observational study","volume":"20","author":"Komiya","year":"2021","journal-title":"Lipids Health Dis."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/0005-2760(96)00066-5","article-title":"The peroxisome proliferator activated receptors (PPARS) and their effects on lipid metabolism and adipocyte differentiation","volume":"1302","author":"Schoonjans","year":"1996","journal-title":"Biochim. Et Biophys. Acta"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"538","DOI":"10.2337\/dc17-1589","article-title":"Effects of Pemafibrate, a Novel Selective PPAR\u03b1 Modulator, on Lipid and Glucose Metabolism in Patients with Type 2 Diabetes and Hypertriglyceridemia: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial","volume":"41","author":"Araki","year":"2018","journal-title":"Diabetes Care"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1056\/NEJMoa1715944","article-title":"Volanesorsen and Triglyceride Levels in Familial Chylomicronemia Syndrome","volume":"381","author":"Witztum","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1093\/eurheartj\/ehab820","article-title":"Apolipoprotein C-III reduction in subjects with moderate hypertriglyceridaemia and at high cardiovascular risk","volume":"43","author":"Tardif","year":"2022","journal-title":"Eur. Heart J."}],"container-title":["Journal of Personalized Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2075-4426\/13\/1\/68\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T01:54:27Z","timestamp":1760147667000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2075-4426\/13\/1\/68"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,28]]},"references-count":31,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,1]]}},"alternative-id":["jpm13010068"],"URL":"https:\/\/doi.org\/10.3390\/jpm13010068","relation":{},"ISSN":["2075-4426"],"issn-type":[{"type":"electronic","value":"2075-4426"}],"subject":[],"published":{"date-parts":[[2022,12,28]]}}}